Sentences with phrase «years drugs companies»

But in the past year the drug company's shares have been one of Wall Street's biggest disasters.

Not exact matches

In the past few years companies like Braeburn Pharmaceuticals, Intarcia Therapeutics, and Proteus Digital Health have set out to create better medical mousetraps through devices that make existing drugs more effective.

The facility where the investigators had assembled that morning, brandishing an Administrative Inspection Warrant, was a distribution center operated by one of America's largest public companies, the giant drug wholesaler McKesson (mck), which ranks No. 5 on this year's Fortune 500.

It all lends credence to Tehrani's claim that, from the outset 15 years ago, he sought to build a different kind of biotechnology firm — «a truly rational drug development company,» as he puts it.

The 32 - year - old Ramaswamy has been able to sway a slew of biopharma vets to lead his companies and take a chance on his audacious, risky approach to drug development.

The past two years alone have seen devastating setbacks for experimental Alzheimer's drugs from a compendium of major pharmaceutical companies.

Shares of pioneering CRISPR gene - editing firm Editas fell 7 % in early Tuesday trading after the company announced that it would delay an initial FDA filing for clinical trials of one of its lead drugs, LCA10, to the middle of next year (Editas had originally planned to file by the end of 2017).

On average, the 30 large and small pharmaceutical and biotech companies IDEA Pharma examined got just 11 % of their 2017 revenue from drugs developed within the past five years, says Mike Rea, the firm's CEO and one of the most insightful people I've met — no exaggeration — when it comes to pinpointing innovation choke points in the drug industry.

Miller, chief investment officer at LMM, said he thinks the embattled drugmaker is «a completely different company» than the one that was under severe fire for jacking up drug prices, and could see returns of 25 percent to 30 percent per year over the next five years.

Sarepta Therapeutics, which won a pioneering Food and Drug Administration approval for its Duchenne muscular dystrophy drug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatmeDrug Administration approval for its Duchenne muscular dystrophy drug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatmedrug last year, has settled a patent dispute with rival BioMarin over the «exon - skipping» technology at heart of the companies» muscular dystrophy treatments.

MONTREAL — Valeant Pharmaceuticals faces years of legal challenges despite cutting ties with a U.S. mail - order pharmacy at the centre of a controversy about how Canada's largest publicly traded drug firm conducts its business, say industry observers and the company's second - largest shareholder.

The company took advantage of a number of U.S. programs meant to spur «orphan drugs,» or treatments for the kinds of disorders that afflict less than 200,000 Americans each year.

Weston said his family, who also controls Loblaw's parent company, George Weston Ltd. (TSX: WN), has undergone some major changes in the past year, including the $ 12.4 - billion blockbuster acquisition of the Shoppers Drug Mart chain.

Vas Narasimhan, a trained physician and former McKinsey consultant who is now global head of development at Novartis, has pursued a wide range of roles in his seven years at the drug company.

Before the insurance company pays a penny toward drugs, she and her husband have to spend $ 7,000 each year.

Through its more than 9,800 retail locations, more than 1,100 walk - in medical clinics, a leading pharmacy benefits manager with more than 94 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand - alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways.

«Shoppers tends to be a Top Five company, but last year was a low point for them with the fight for generic drugs,» says Susan Quinn - Mullins, a senior adviser to the Research Institute.

Walmsley has been in place for around a year, but has already replaced nearly half of GSK's top executive team and has made sweeping changes in its R&D team, while shutting down many of its clinical drug trials in an effort to narrow the company's portfolio.

And after announcing a «social contract» to keep drug price hikes below 10 percent a year, his company raised a slew of prices by 9.5 percent.

In November, Denner helped facilitate the sale of hemophilia drug maker Bioverativ, for $ 11.6 billion, to Sanofi, a little more than a year after the company was spun out of Biogen, of which Denner is a director.

Concerns that a Hillary Clinton administration would impose greater price regulation on drug companies had put a damper on pharmaceutical stocks for more than a year.

Only about 200 patients or fewer will take Valeant's branded version of the migraine drug this year, amounting to less than $ 1 million in sales (about 0.01 % of the company's annual revenue).

After generic drug maker Actavis bought Allergan last year, it took the name of the specialty pharmaceutical company; the reinvented Allergan then turned around and sold its legacy generic business to Teva Pharmaceutical Industries (TEVA) in July.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

Revenue growth has slowed as many companies sink more resources into developing the next blockbuster drug; what's more, the «patent cliff» for the last round of megabillion - dollar drugs — when generics firms typically see a sales spurt — happened a few years ago.

(Currently, there is a shortage of Valeant's Nitropress, a heart drug that is off - patent but has no generic version — despite the company having tripled the drug's price «overnight» last year, according to the House committee.)

Numerous drug companies have been criticized for the increased prices of some medications in the past few years.

LONDON, Feb 6 - After nearly a century building a company worth $ 125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.

ASH 2016 has been one of the most anticipated scientific conventions of the year, with companies like Novartis, Kite, and Juno presenting critical new data about a next - gen set of drugs that are being tested in numerous blood cancers.

A Wall Street Journal investigation earlier this year linked companies controlled by Canada Drugs through its wholesale division to a shipment of a fake cancer drug, though the FDA hasn't reached a conclusion.

While Yervoy brought in $ 960 million in sales in 2013 (an enormous figure for a two - year - old drug with a small patient population), the company currently has more than 35 ongoing clinical trials investigating another drug that disengages the immune system's brakes: the much - awaited nivolumab, which was also from the Medarex portfolio.

Eagle's Sassouni pointed out that since the big drug companies are losing billions of dollars every year to generic versions and have little to spend on their own research and development, they are looking to buy smaller biotechnology companies that are developing their own products.

Yes, the model that most major drug companies are hoping to emulate these days isn't Pfizer (No. 51 on this year's Fortune 500), but rather Bristol - Myers Squibb, No. 176 — which is down from No. 158 in 2013 and a rank of No. 134 the year before.

When Sarepta Therapeutics nabbed a pioneering approval for a Duchenne muscular dystrophy (DMD) drug last year, it won more than just bragging rights and a controversial FDA approval: the firm also landed a coveted «priority review voucher,» which can either be sold off to another company or used to slash the review period for a future Sarepta treatment.

Shares of the drug company have falling since the middle of last year on allegations of account fraud and price gouging.

For months, if not years, people wondered how Pfizer, the company that sold the drug, would survive after its cash cow of a pill stopped providing the milk.

The investors are frustrated that shares in Jazz, a $ 9 billion pharmaceutical company known for its narcolepsy drug Xyrem, have remained essentially flat over the past year.

According to Ackman, Valeant has spent $ 40 billion acquiring drugs or drug companies in the past five years or so.

Now Mylan appears to be learning the same hard lesson this week that Martin Shkreli and Valeant (vrx) learned last year: Investors love when pharmaceutical companies raise drug prices — until everybody else gets really upset about it.

The price of the EpiPen has soared 500 % since generic drug company Mylan (myl) bought the treatment nine years ago.

This is quite a big deal as Valeant bought Sprout Pharmaceuticals, the company behind the drug for a whopping $ 1 billion just over two years ago.

After years of buying up companies then raising the prices of their drugs — a strategy that rapidly amplified Valeant's revenue and stock price — Valeant is now struggling to grow by other means, while dealing with the consequences of its previous actions.

Cindy Whitehead, the founder and COO of the Raleigh, North Carolina - based company, has been fighting to get the drug approved for four years.

The campaign also said that Prop 61 «would invalidate many drug discount agreements the state has negotiated with pharmaceutical companies,» which would increase state prescription costs by tens of millions of dollars each year.

Looking at the portfolio, the company's Innovative Health segment, which sells newer, patent - protected drugs, contributed sales of $ 7.42 billion, representing growth of 5 % year over year.

But the company was hit by regulatory and political scrutiny in the past year over its drug pricing and its relationship to a mail - order pharmacy, and its stock took a beating.

Profit declines sharply and company cuts full - year outlook

Cardinal Health Inc. reported a sharp decline in profit in its last quarter and lowered its full - year outlook following inventory write - downs in its overseas businesses and a sharper - than - anticipated decline in generic drug prices.

Such big winners stopped showing up a few years ago, leaving the large drug companies watching the calendar for the day when earnings would be hurt by the loss of key patent protections.

However, I believe that new drug approvals, a solid pipeline and the company's deals and acquisitions will pave the way for growth this year

Over the past three decades, the Tufts Center for the Study of Drug Development has estimated both the cost and the years it takes for companies to develop new medicines.